Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Urologic ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The long and tortuous history of the discovery of testosterone and its clinical application.J Sex Med. 2013; 10: 1178-1183
- A brief history of testosterone.J Urol. 2001; 165: 371-373
- Testosterone treatment comes of age: new options for hypogonadal men.Clin Endocrinol. 2006; 65: 275-281
- Testosterone and cardiovascular disease–the controversy and the facts.Postgrad Med. 2014; 127: 159-165
- Endocrines: the use of testosterone.N Engl J Med. 1940; 222: 877-881
- The effect of castration, of estrogen and of androgen injection on serum phosphatase on metastatic carcinoma of the prostate.Cancer Res. 1941; 1: 293-297
- Trends in androgen prescribing in the United States, 2001 to 2011.JAMA Intern Med. 2013; 173: 1465-1466
- Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men.Andrology. 2014; 2: 819-834
- A new era of testosterone and prostate cancer: from physiology to clinical implications.Eur Urol. 2014; 65: 115-123
- Testosterone and prostate cancer: what are the risks for middle-aged men?.Urol Clin North Am. 2011; 38: 119-124
- Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland.Arch Surg. 1941; 43: 209-223
- The response of metastatic adenocarcinoma of the prostate to exogenous testosterone.J Urol. 1981; 126: 372-375
- Goodbye androgen hypothesis, hello saturation model.Eur Urol. 2012; 62: 765-767
- Turning conventional wisdom upside-down.Cancer. 2011; 117: 3885-3888
- Rapidly shifting concepts regarding androgens and prostate cancer.ScientificWorldJournal. 2009; 9: 685-690
- Prostate cancer and testosterone replacement therapy-what is the risk?.J Urol. 2015; 194: 1527-1528
- Occult prostate cancer in men with low serum testosterone levels.JAMA. 1996; 276: 1904-1906
- Prevalence of prostate cancer among men with a prostate-specific antigen level≤ 4.0 ng per milliliter.N Engl J Med. 2004; 350: 2239-2246
- Testosterone and prostate cancer: an historical perspective on a modern myth.Eur Urol. 2006; 50: 935-939
- Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.J Natl Cancer Inst. 2008; 100: 170-183
- Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial.Eur Urol. 2012; 62: 757-764
- Risks of testosterone-replacement therapy and recommendations for monitoring.N Engl J Med. 2004; 350: 482-492
- Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men.J Urol. 1998; 159: 441-443
- Testosterone dose-response relationships in healthy young men.Am J Physiol Endocrinol Metab. 2001; 281: 1172-1181
- Response of men with advanced prostatic carcinoma to exogenous administration of testosterone.Cancer. 1967; 20: 1871-1878
- Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.Eur Urol. 2009; 55: 310-321
- Testosterone replacement therapy and prostate cancer.Urol Clin North Am. 2007; 34: 555-563
- Testosterone therapy in men with prostate cancer: literature review, clinical experience, and recommendations.Asian J Androl. 2015; 17: 206
- Androgen receptor levels and androgen contents in the prostate lobes of intact and testosterone-treated noble rats.J Androl. 1985; 6: 279-290
- Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates.Prog Clin Biol Res. 1988; 262: 145-160
- Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.JAMA. 2006; 296: 2351-2361
- Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging.J Clin Endocrinol Metab. 2001; 86: 724-731
- To treat or not to treat with testosterone replacement therapy: a contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer.Curr Urol Rep. 2014; 15: 1-10
- Testosterone deficiency.Am J Med. 2011; 124: 578-587
- Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.J Gerontol A Biol Sci Med Sci. 2005; 60: 1451-1457
- Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review.Int J Impot Res. 2009; 21: 9-23
- Is testosterone treatment good for the prostate? Study of safety during long-term treatment.J Sex Med. 2012; 9: 2138-2149
- Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship.Eur Urol. 2007; 52: 623-625
- Is low serum free testosterone a marker for high grade prostate cancer?.J Urol. 2000; 163: 8247
- High-grade prostate cancer is associated with low serum testosterone levels.Prostate. 2001; 47: 52-58
- Testosterone levels in benign prostatic hypertrophy and prostate cancer.Urol Int. 2008; 80: 134-140
- Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.BJU Int. 2012; 110: E541-E546
- Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy.Cancer. 2011; 117: 3953-3962
- Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy.Eur Urol. 2007; 52: 696-701
- Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance.BJU Int. 2014; 114: 229-235
- Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.Urology. 2013; 82: 321-326
- Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.J Urol. 2004; 172: 920-922
- Testosterone replacement therapy after primary treatment for prostate cancer.J Urol. 2005; 173: 533-536
- Testosterone replacement therapy following radical prostatectomy.J Sex Med. 2009; 6: 1165-1170
- Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.J Urol. 2013; 190: 639-644
- Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.Cancer. 2007; 109: 536-541
- Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.BJU Int. 2009; 103: 62-64
- Testosterone replacement therapy in the setting of prostate cancer treated with radiation.Int J Impot Res. 2013; 25: 24-28
- Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer.BJU Int. 2014; 114: 125-130
- Testosterone therapy after radiation therapy for low, intermediate, and high risk prostate cancer.J Urol. 2015; 194: 1271-1276
- Testosterone therapy in men with untreated prostate cancer.J Urol. 2011; 185: 1256-1260
- Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results.Asian J Androl. 2016; 18: 16-20
- Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.BJU Int. 2011; 107: 1369-1373
Article info
Footnotes
Disclosure Statement: Dr A. Morgentaler has received payments for research, consulting, lecture honoraria, and/or scientific advisory boards for AbbVie, Antares, Bayer, Clarus, Eli Lilly (27705), Endo (201107293), and Pfizer. Ms E. Davidson has no conflicts to declare.
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.
